Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


   Infocentre

Last Update: 04-07-2014  
Related category(ies):
Health & life sciences  |  Success stories  |  SMEs

 

Countries involved in the project described in the article:
Belgium  |  Germany  |  Hungary  |  Italy  |  Spain  |  Sweden  |  Switzerland  |  United Kingdom
Add to PDF "basket"

New tools to fight tuberculosis and other chronic infections

A groundbreaking European research project focused on tuberculosis (TB) diagnosis and treatment has developed potentially life-saving novel drug candidates and new diagnostics for the condition.

image of syringe on an x-ray image © sudok1 - Fotolia.com

TB is one of the world’s most persistent diseases, and even today, despite medical advances, it still claims around 1.45 million lives worldwide each year. A key reason TB is still a menace is inadequate diagnosis and the ability of the TB-pathogen to adapt to antibiotics. Its drug resistance is a public health problem that threatens progress made in TB care and control worldwide.

The project, NOPERSIST, applied advances in molecular biology and the sequencing of TB genomes (the genetic material of an organism) to better understand the disease and other infections such as HIV.

The research team used novel strategies that could lead to efficient and accurate TB diagnosis and treatment of other persistent infections. These results include the world's first blood test for active TB; a rapid, three-hour test for bovine TB; a novel drug cocktail candidate for multi-drug-resistant tuberculosis (MDR-TB); a new drug candidate for TB; and molecular tests for diseases in pigs. NOPERSIST team also successfully developed a novel adjuvant – or vaccine booster - that could be widely used to create all kinds of vaccines, not only for TB.

The project’s breakthroughs are even more exceptional given that diagnoses of these infections are extremely difficult and time-consuming, and no efficient, cost effective tests have been available until now.

“NOPERSIST has been unusually innovative which is evident by the fact that five European patents have been filed out of the project,” says NOPERSIST’s project coordinator Prof. Mahavir Singh, from Lionex, a biotech company based in Brunswick, Germany.

Prof. Singh explains that much of the success was down to the application of medical advances in molecular biology and the availability of new information generated after sequencing the TB genome.

“Molecular biology and immunology helped significantly in discovering and developing novel biomarkers as a diagnostic test, as well as a novel adjuvant,” he says. “In addition, genome sequencing helped partners focus on veterinary diseases in cattle and swine. Tests based on genome sequencing results will shortly be developed for some veterinary diseases.”

Prof. Singh adds that with a diagnostic market of TB worth nearly €1 billion, NOPERSIST’s new leads could bring novel products on the market, delivering a major competitive advantage to European industry. “The new active TB tests have an excellent chance of becoming the major diagnostic tool for TB,” he says. Further research planned under the follow-up project, Demo-NOPERSIST, is expected to bring the diagnostic products on the market within the next 2-3 years.

Prof. Singh believes the project team has not merely learnt about the mechanisms of drug resistance in TB and improved current techniques for rapid detection, but it has also stimulated the exploration of new targets for drug activity and drug development. “NOPERSIST project was a good example of how a motivated research team performing a highly ambitious project with a small budget can really achieve its objectives, and have significant social and economic impact on human health in Europe and elsewhere,” he concludes.

Nearly nine million people around the world became sick with TB in 2011, according to the US-based Center for Disease Control and Prevention.Drug-resistant TB - which occurs when the bacteria develops the ability to withstand antibiotic attack - is difficult and costly to treat. It can be fatal, and an estimated 650,000 people worldwide have MDR-TB.

Project details

  • Project acronym: NOPERSIST
  • Participants: Germany (Coordinator), Sweden, UK, Switzerland, Hungary, Italy, Belgium, Spain
  • FP7 Proj. N° 232188
  • Total costs: € 1 714 410
  • EU contribution: € 1 319 990
  • Duration: January 2010 - December 2012

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site

Project information on CORDIS

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center